THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company involved in the development and commercialization of cell therapies, today announced that Jim Williams, Ph.D., the Company’s chief operating officer, research & development, will present at the Cambridge Healthtech Institute’s Targeted Immunotherapeutics & Vaccines Summit on August 24, 2007 at 8:35 a.m. EDT. Dr. Williams’ presentation, “Paving the Way for Autologous Cell Therapy for Autoimmunity,” will focus on Opexa’s unique technology platform, which uses attenuated pathogenic T-cells, in the development of patient-specific immunotherapies for the treatment of autoimmune diseases amenable to T-cell based therapies. These diseases include multiple sclerosis, rheumatoid arthritis and Type 1 diabetes.
